P1.07-008 Microbiome & Immunotherapy: Antibiotic Use Is Associated With Inferior Survival for Lung Cancer Patients Receiving PD-1 Inhibitors

Journal of Thoracic Oncology- United States

doi 10.1016/j.jtho.2017.09.926

Full Text

Abstract

Available in

Categories

Respiratory Medicine

Date

November 1, 2017

Authors

Publisher

Elsevier BV

Related search

MA10.01 Antibiotic Use and PD-1 Inhibitors: Shorter Survival in Lung Cancer, Especially When Given Intravenously. Type of Infection Also Matters

Journal of Thoracic Oncology

Respiratory Medicine

English

PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer

Medicinski podmladak

English

Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated With PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy

Frontiers in Immunology

English

Gut Microbiome Affects the Response to Anti-Pd-1 Immunotherapy in Patients With Hepatocellular Carcinoma

Journal for ImmunoTherapy of Cancer

Molecular Medicine

Cancer Research

English

Design of PD-L1 Inhibitors for Lung Cancer

English

PD‑L1 Expression Is Associated With Advanced Non‑small Cell Lung Cancer

Oncology Letters

Cancer Research

English

Reduced PLCG1 Expression Is Associated With Inferior Survival for Myelodysplastic Syndromes

Cancer Medicine

Cancer Research

Nuclear Medicine

English

Cancer Immunotherapy: PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy (Adv. Mater. 22/2018)

Advanced Materials

Mechanics of Materials

Materials Science

Mechanical Engineering

English

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English